Abstract book - ESTRO meets Asia

S55 ESTRO meets Asia 2018

Results There were 113 patients in total in our study, aged between 22.0 and 66.9 years. The average age in the TPF and GP groups were 45.9 (22–66) and 48.2 (26–65) years, respectively (P=0.375). All patients accepted induction chemotherapy plus CCRT. The average follow-up time was 51.4 (16.8–98.3) months. Ninety-four patients (83.2%) were alive after 36-months follow-up. The median overall survival (OS) and progression-free survival (PFS) time were 48.3 and 39.7 months, respectively. The 3-year OS for the TPF regimen was 87.9% and 87.4% with GP chemotherapy (P=0.928). The 3-year PFS of the TPF treatment was 84.5%, while it was 83.5% for the GP group (P=0.551). OS (Log- Rank P=0.928) and PFS (Log-Rank P=0.551) did not differ significantly between the two groups. Patients in the TPF induction chemotherapy plus CCRT group, did not show better LRFS outcomes in comparison to those in the GP induction group (Log-Rank P=0.073). Furthermore, DMFS rates were not different between the treatment groups (Log-Rank P=0.892). Conclusion There were no significant differences in adverse toxicities or treatment efficacy between the chemotherapy regimens in the treatment of locoregionally advanced NPC. Furthermore, the adverse toxicities were similar and could be tolerated. PO-140 Induction chemo followed by rt vs. Surgery followed by ccrt in locally advanced scc of oral cavity S.H. A. Ali 1 , J. Mallick 2 , A.H. Lakhna 2 1 Ziauddin University, Radiation Oncology, Karachi, Pakistan 2 Ziauddin University Hospital, Radiation Oncology, Karachi, Pakistan Purpose or Objective Squamous cell carcinoma of the oral cavity is placed amongst the top ten malignancies globally. Pakistan has a high incidence of oral cancers due to the prevailing bad habits/addictions and most patients present with stage III or IV locally advanced disease. Recommended guidelines indicate surgery as the mainstay of treatment followed by radiation therapy (RT). The addition of induction chemotherapy before surgery or radiation therapy has improved outcomes with increased loco- regional control rates. Material and Methods This is a retrospective study with two arms compared in locally advanced Stage IV-A and IV-B head and neck tumors (excluding primary sites nasopharynx, larynx, thyroid, salivary glands and nose/paranasal sinuses). It was conducted in the Department of Oncology, Ziauddin University Hospital, Karachi, Pakistan. After screening from the inclusion and exclusion criteria, data of patients were searched out from patients’ files with histological diagnosis of squamous cell carcinoma of oral cavity. Data was searched from 2010 to 2014. The previously untreated patients in the 1 st arm were surgically operated and later on postoperative radiotherapy was given to a dose of 66 Gy. In the 2 nd arm neoadjuvant chemotherapy was given 2-3 cycles with Docetaxel 75 mg/m2 day1, Cisplatin 75 mg/m2 day2 and 5-Fluorouracil 1000 mg/m2 day2-5 followed by radiation therapy upto 66 Gy. Results A total of 90 patients with squamous cell carcinoma of oral cavity were enrolled in this study as non-trial cohort with 45 patients in each arm. There were 60 males and 30 females. 27 patients developed grade III and IV neutropenia in Arm 2, however most patients in Arm1 had no neutropenia. Similarly 27 patients developed grade III oral mucositis in Arm 2 and only 18 patients developed grade III mucositis in Arm 1. We found out that the mean PFS among patients undergoing surgery and CCRT was 6.40

(± 2.38) months while those who received Induction Chemotherapy followed by RT was 7.6 (±4.76) months.

Conclusion The results compared showed improved progression free survival in the 2 nd arm with bad toxicity profile. In this study from a single institute the results seem very encouraging. The results however are not statistically significant but still they open a new horizon for the treatment of head and neck cancers. PO-141 Outcomes of Definitive Chemoradiation for Nasopharyngeal Cancer: A Single Institution Experience. K. Venkatesan 1 , V. Anand 1 , R. Bajpai 1 , V. Babu 1 , A. Kolse 1 , S. Deshpande 1 , S. Naidu 1 , S. Almel 2 , M. Shaikh 2 , M. Lala 3 , S. Pradhan 3 , M. Kirtane 4 , A. Kapadia 2 1 P D Hinduja Hospital, Radiation Oncology, Mumbai, India 2 P D Hinduja Hospital, Medical Oncology, Mumbai, India 3 P D Hinduja Hospital, Surgical Oncology, Mumbai, India 4 P D Hinduja Hospital, ENT Surgeon, Mumbai, India Purpose or Objective The aim of this study is to report long-term results of definitive chemoradiation therapy for nasopharyngeal carcinoma (NPC) in a non-endemic cohort of patients. Material and Methods Between January 1999 and December 2017, a total of 61 biopsy proven NPC patients who received definitive chemoradiotherapy at our institution were analyzed retrospectively. Rates of local control, distant control, disease-free survival and overall survival were calculated from the date of biopsy using Kaplan-Meier method. Results Median follow-up was 56 months (range, 3-211 months). The median age was 40 years (range, 10-77 years) and the male to female ratio was 4.5:1. Most of the tumor histopathology was undifferentiated nonkeratinizing carcinoma (74%). The number of patients staged with I, II, III and IV were 1 (1.6%), 10 (16%), 26 (43%) and 24 (39%), respectively. Platinum based chemotherapy was administered to 96.5%, including 56% who received concurrent and adjuvant chemotherapy. 6.5% received concurrent chemotherapy alone, and 34% received induction chemotherapy with or without concurrent chemotherapy. Seventy-nine percent received intensity modulated radiotherapy. Median RT dose was 70Gy. For all patients, the 5-year local control, distant control, overall survival and disease-free survival were 75.6%, 67.9%, 66.4% and 64.2%, respectively. Conclusion Our data suggest excellent local and distant control among nasopharyngeal cancer patients treated with definitive chemoradiotherapy.